No abstract

Wheat bran was shown to provide protection against colorectal cancer in human intervention and animal studies. Our recent study showed, however, that antitumor activities of wheat bran from various wheat cultivars differed significantly even when wheat fiber was equal in diets. We hypothesized that phytochemical lignans in wheat bran may account for the differences among wheat cultivars in cancer prevention. The concentration of a major lignan, secoisolariciresinol diglycoside, was determined by HPLC in 4 selected wheat cultivars (i.e., Madison, Ernie, Betty, and Arapahoe). The lignan concentrations and their antitumor activities, previously determined in APC-Min mice, were correlated (r = 0.73, P < 0.02). The cancer preventive mechanisms of 2 prominent lignan metabolites (enterolactone and enterodiol) were further studied in human colonic cancer SW480 cells. Treatment with enterolactone and enterodiol, alone or in combination, at 0-40 micromol/L resulted in dose- and time-dependent decreases in cell numbers. Although the cytotoxicity as measured by trypan blue staining in adherent cells was not affected, DNA flow cytometric analysis indicated that the treatments induced cell cycle arrest at the S-phase. Western blot analysis for cyclin A, a required protein for S/G2 transition, showed that the cyclin A protein levels decreased after treatment with enterodiol or the combination of enterolactone and enterodiol at 40 micromol/L for 72 h. Apoptosis analysis by the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay showed an increased percentage of apoptotic cells in the floating cells after enterodiol alone or combined treatments. These results suggest for the first time that lignans may contribute, at least in part, to the cancer prevention by wheat bran observed in APC-Min mice. Inhibition of cancer cell growth by lignan metabolites seems to be mediated by cytostatic and apoptotic mechanisms.

Promising anti-breast cancer agents derived from substituted quinolines were discovered. The quinolines were readily synthesized in large scale from a sequence of reactions starting from 4-acetamidoanisole. The Michael addition product was isolated as the reaction intermediate in the ring closing reaction of 4-amino-5-nitro-2-(3-trifluoromethylphenyloxy)anisole with methyl vinyl ketone leading to 6-methoxy-4-methyl-8-nitro-5-(3-trifluoromethylphenyloxy)quinoline (14). The amino function of 8-amino-6-methoxy-4-methyl-5-(3-trifluoromethylphenyloxy)quinoline, prepared from 14, was connected to various side chains via alkylation with N- (3-iodopropyl)phthalimide, Michael addition with acrylonitrile, and reductive amination with various heterocycle carboxaldehydes, such as imidazole-4-carboxaldehyde, thiophene-2-carboxaldehyde, and 2-furaldehyde. Effects of the substituted quinolines on cell viability of T47D breast cancer cells using trypan blue exclusion assay were examined. The results showed that the IC 50 value of 6-methoxy-8-[(2-furanylmethyl)amino]-4-methyl-5-(3-trifluoromethylphenyloxy)quinoline is 16 ± 3 nM, the lowest IC 50 out of all the quinolines tested. IC 50 values of three other quinolines are in the nanomolar range, a desirable range for pharmacological testing. Keywordssynthesis of substituted quinolines; anti-breast-cancer agents; T47D breast cancer cells Quinolines are known for their anti-malarial, 1-3 leishmanicidal, 4 antibacterial 5 and anticancer activities. 6-9 Recently, quinolines were examined in ATP-binding cassette drug transporter inhibition, 6 targeting tumor hypoxia, 7 modulation of multidrug resistance, 8 and tyrosine kinase inhibition. 9 Based on these literature results, we investigated substituted quinolines in search of novel anti-breast cancer compounds. After our initial anticancer screening, we focused on substituted quinolines with a skeletal structure derived from 8-amino-5-(aryloxy)-6-methoxy-4-methylquinoline, 1 by derivatizing its C8-amino side chain. We report † This manuscript is dedicated to Professor E. J. Corey on the occasion of his 80 th birthday. *Corresponding author. Tel.: 785-532-6699; fax: 785-532-6666; e-mail: duy@ksu.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access Author ManuscriptBioorg Med Chem Lett. Author manuscript; available in PMC 2009 June 1. We utilized a similar synthetic method leading to 5-(aryloxy)-4-methylprimaquine 1,10 by starting with 4-acetamidoanisole (8) via sequential C2 and C5 functionalizations followed by a ring closing reaction. Hence, 2-bromo-4-acetamino-5-nitro...

Activation of PKCgamma by TPA or IGF-1 stimulated the interaction of PKCgamma with Cav-1 and Cx43 in lipid rafts, causing Cx43, Cav-1, and PKCgamma to redistribute within the lipid rafts, and this resulted in a decrease in gap junction plaques.

PKCgamma mediated IGF-I-induced decreases in gap junctional communication through interaction with and phosphorylation of Cx43. IGF-I caused an increase in DAG, and this increased translocation of PKCgamma, whereas mobilization of calcium was not essential for IGF-I-stimulated translocation of PKCgamma.